Oncology cost growth is expected in the 7.5% to 10.5% range annually through 2020, when global oncology costs will exceed $150 billion

Chart 20: Global Oncology Costs and Growth, 2010–2020

- Higher costs will be driven by the wider usage of new products, especially immunotherapies, in developed markets such as the U.S. and the five major European countries.
- Newer therapies with survival benefits will also bring longer therapy durations.
- Patient not currently candidates for cancer therapy may be able to take advantage of new options and lines of therapy.
- The use of newer treatments will be offset by lower usage of existing treatments, some of which are already off patent and available as generic medicines.
- Patent expiries and biosimilar competition will contribute to lower costs but will be offset by increased prevalence, diagnosis rates and treatment rates.
- Since 2013, growth in EU5 has rebounded driven by new medicines and this continued wave of innovation is expected to lift growth to 2020.

Chart notes: